Clinical TrialJul 8, 2026, 07:12 AM
BioLineRx & Hemispherian GLIX1/PARPi Synergy in Ovarian Cancer
AI Summary
BioLineRx and Hemispherian announced highly encouraging new preclinical data demonstrating a strong synergistic effect between GLIX1 and PARP inhibitors in a patient-derived ovarian cancer xenograft model. The combination of GLIX1 and olaparib showed substantially better efficacy than individual drugs and comparable efficacy to cisplatin, suggesting GLIX1 can broaden PARP inhibitor use in HR-proficient ovarian cancer. BioLineRx plans to include an ovarian cancer arm in its ongoing Phase 1/2a study.
Key Highlights
- BioLineRx & Hemispherian reported strong GLIX1/PARPi synergy in ovarian cancer PDX model.
- Combination of GLIX1 and olaparib showed better efficacy than monotherapies at low doses.
- GLIX1/olaparib combination efficacy was comparable to chemotherapy drug cisplatin.
- Data reinforces synthetic lethality between GLIX1 and PARP inhibitors.
- GLIX1 has potential to broaden PARPi use in HR-proficient ovarian cancer.
- BioLineRx plans to add an ovarian cancer arm to its ongoing Phase 1/2a study.
Price Impact
More from BLRX